SCHEDULE 13D/A: Bp4 S.r.l. Undergoes Liquidation, Shifts Control of 12.35% Stake in Milestone Scientific Inc.

Bp4 S.r.l., a significant shareholder in Milestone Scientific Inc., has entered voluntary liquidation, transferring sole control of its 12.35% stake to a newly appointed liquidator, Dr. Pedro Palau, who will manage the investment with a mandate to repay creditors and distribute assets.

Summary

• Bp4 S.r.l., the reporting person, holds 9,672,192 shares of Milestone Scientific Inc. Common Stock, representing 12.35% of the issued and outstanding shares.
• The Reporting Person has initiated a voluntary plan of liquidation under Italian law.
• Effective February 1, 2025, Dr. Pedro Palau was appointed as the legal representative and liquidator, replacing the previous board of directors of Bp4 S.r.l.
• Dr. Palau now possesses sole voting and dispositive power over the 9,672,192 shares of Milestone Scientific Inc. held by Bp4 S.r.l.
• The liquidator's primary mandate is to repay creditors and subsequently distribute the remaining assets of Bp4 S.r.l. to its constituent parties.
• In the course of the liquidation, the liquidator will review the investment in Milestone Scientific Inc., monitoring factors such as trading prices, the issuer's financial position, operations, assets, prospects, and strategic direction.
• The Reporting Person may sell some of its Milestone Scientific Inc. shares to cover its operating expenses before the final distribution of assets.
• Previous reporting persons, Innovest S.p.A and Mr. Giandomenico Trombetta, no longer control Bp4 S.r.l.'s shares and now each own less than 1% of Milestone Scientific Inc. as of February 1, 2025.

Sentiment

Score: 5

Explanation: Neutral. The filing reports a factual change in beneficial ownership and control due to a shareholder's liquidation. While the potential sale of shares could be negative, the filing itself is a procedural update without explicit positive or negative performance implications for the issuer.

Positives

• The appointment of a liquidator provides a clear framework for the management and eventual disposition of Bp4 S.r.l.'s significant stake in Milestone Scientific Inc.
• The liquidator's mandate to review the investment could lead to strategic decisions aimed at maximizing the value of the holding, potentially benefiting the issuer.

Negatives

• The voluntary liquidation of Bp4 S.r.l. implies a winding down of its operations, which could result in the sale of its substantial 12.35% stake in Milestone Scientific Inc.
• Potential future sales of a large block of shares (9,672,192 shares) by the liquidator could create downward pressure on Milestone Scientific Inc.'s stock price due to increased supply.

Risks

• The liquidator of Bp4 S.r.l. may be compelled to sell some or all of the 9,672,192 shares of Milestone Scientific Inc. Common Stock to satisfy creditor obligations or facilitate asset distribution, which could negatively impact the issuer's share price.
• The change in control over a significant shareholder's stake introduces uncertainty regarding future voting patterns and potential influence on Milestone Scientific Inc.'s strategic direction.

Future Outlook

The Reporting Person, through its liquidator, will review its investment in Milestone Scientific Inc. and monitor various investment considerations, including current and anticipated future trading prices for the Common Stock, the issuer's financial position, operations, assets, prospects, and strategic direction. The liquidator may acquire or dispose of Common Stock (or other securities), change its current intentions, or engage in hedging, derivative, or similar transactions. As a shareholder, the Reporting Person may propose and encourage or vote for the issuer to engage in acquisition and disposition transactions and to enter into financing transactions that may change the capitalization of the issuer.

Management Comments

• "The general mandate of Dr. Palau, as liquidator, is to repay creditors and then distribute the assets of the Reporting Person to its constituent parties."
• "In the context of the administration of the liquidation, the Reporting Person will review its investment in the issuer and will monitor a wide variety of investment considerations..."
• "The Reporting Person will also evaluate its cash requirements for its operating expenses, which may require Reporting Person to sell some of the shares of Common Stock in the issuer, prior to any distribution of the remaining assets to its constituent parties."

Industry Context

This filing primarily concerns a change in beneficial ownership and control of a significant stake in Milestone Scientific Inc. due to the liquidation of a major shareholder, Bp4 S.r.l. It does not directly reflect broader industry trends but highlights the potential for a large block of shares to enter the market, which is a common consideration in investment analysis regarding supply and demand dynamics.

Management Changes

Stakeholder Impact

• Shareholders: Potential impact from future sales of a large block of shares by the liquidator, which could affect stock price. Uncertainty regarding the long-term intentions of a significant shareholder.
• Creditors of Bp4 S.r.l.: The liquidation process is intended to repay their outstanding debts.

Next Steps

• The liquidator, Dr. Pedro Palau, will proceed with the administration of Bp4 S.r.l.'s liquidation, including the repayment of creditors and the distribution of assets.
• The liquidator will conduct an ongoing review of Bp4 S.r.l.'s investment in Milestone Scientific Inc., monitoring various market and company-specific factors.
• The liquidator may undertake actions such as acquiring or disposing of Milestone Scientific Inc. shares, potentially including sales to cover operating expenses.
• The Reporting Person, through its liquidator, may propose or vote for Milestone Scientific Inc. to engage in acquisition, disposition, or financing transactions.

Key Dates

Recommendation

Keywords

Milestone Scientific Inc., Bp4 S.r.l., Schedule 13D, Beneficial Ownership, Liquidation, Shareholder, Investment, Common Stock, SEC Filing, Corporate Governance, Dr. Pedro Palau